CN Patent

CN117677385A — 用于治疗肝病的培马贝特和/或托格列净

Assigned to Kowa Co Ltd · Expires 2024-03-08 · 2y expired

What this patent protects

培马贝特、托格列净及其组合用于治疗患有肝病的人患者，特别是患有肝硬化或肝纤维化的NASH患者、患有小叶炎症的NASH患者、具有升高的LDL‑C的NASH患者和具有健康甘油三酯水平的NASH患者。

USPTO Abstract

培马贝特、托格列净及其组合用于治疗患有肝病的人患者，特别是患有肝硬化或肝纤维化的NASH患者、患有小叶炎症的NASH患者、具有升高的LDL‑C的NASH患者和具有健康甘油三酯水平的NASH患者。

Drugs covered by this patent

Patent Metadata

Patent number: CN117677385A
Jurisdiction: CN
Classification: —
Expires: 2024-03-08
Drug substance claim: No
Drug product claim: No
Assignee: Kowa Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.